Figure 1.

Rotarod motor coordination and balance performance in 6-mo-old WT and Ube3a mice given three consecutive daily training trials for 3 d, and treated with either vehicle or the TrkB receptor agonist 7,8-dihydroxyflavanone (7,8-DHF, 5 mg/kg i.p.), showed no improvement with treatment. Consistent with previous reports for Ube3a mice at younger ages, middle-aged Ube3a mice displayed initial and continuing deficits on rotarod performance as compared to WT (for all figures, please see Results text for full statistical analyses). (A) WT in both the vehicle and 7,8-DHF groups improved across training days, displaying increasingly longer latencies to fall across training days 1, 2, and 3, indicating normal motor learning. No significant difference was detected between WT treated with vehicle versus 7,8-DHF. (B) Ube3a in both the vehicle and 7,8-DHF treatment groups improved across training days, although latencies to fall remained lower than in WT, as expected. No significant difference was detected in performance between Ube3a mice treated with vehicle versus 7,8-DHF.